Pharmaceutical - USA, Eli Lilly

Filter

Current filters:

USAEli Lilly

Popular Filters

1 to 25 of 31 results

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

03-03-2015

US drug major Eli Lilly has licensed late-stage neuroscience drug pomaglumetad methionil (mGlu2/3 receptor…

Eli LillyLicensingNeurologicalPharmaceuticalpomaglumetad methionilUSA

Eli Lilly delays US and Europe filings for new diabetes agent peglispro

23-02-2015

US pharma major Eli Lilly says it is delaying the submission of its basal insulin peglispro (BIL) to…

DiabetesEli LillyEuropepeglisproPharmaceuticalRegulationUSA

Lilly accepts committee recommendation to extend evacetrapib study by six months

Lilly accepts committee recommendation to extend evacetrapib study by six months

20-02-2015

US drug major Eli Lilly has accepted the recommendation of the ACCELERATE study academic executive committee…

Cardio-vascularEli LillyevacetrapibPharmaceuticalResearchUSA

FTC puts conditions on Eli Lilly’s proposed acquisition of Novartis Animal Health

23-12-2014

US pharma major Eli Lilly has agreed to divest its Sentinel product line of medications for treating…

Eli LillyMergers & AcquisitionsNovartisPharmaceuticalUSA

Eli Lilly receives marketing authorization from the European Commission for Cyramza

Eli Lilly receives marketing authorization from the European Commission for Cyramza

22-12-2014

Eli Lilly has received marketing authorization from the European Commission for its drug Cyramza.

CyramzaEli LillyOncologyPharmaceuticalUSA

FDA approves third indication for Lilly’s Cyramza

FDA approves third indication for Lilly’s Cyramza

13-12-2014

The US Food and Drug Administration on Friday expanded the approved use of pharma major Eli Lilly’s…

CyramzaEli LillyOncologyPharmaceuticalRegulationUSA

Takeda and Lilly’s fine is reduced in Actos case

Takeda and Lilly’s fine is reduced in Actos case

28-10-2014

A US district court has reduced the damages to be paid by Japan’s largest drugmaker Takeda Pharmaceutical…

ActosDiabetesEli LillyLegalPharmaceuticalTakeda PharmaceuticalUSA

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

23-10-2014

US drug major Eli Lilly reported third quarter 2014 results that showed how badly the company has been…

CymbaltaEli LillyEli Lilly and CompanyEvistaFinancialPharmaceuticalUnited StatesUSA

Lilly expands collaboration with Zymeworks

Lilly expands collaboration with Zymeworks

23-10-2014

US pharma major Eli Lilly and privately-held Canadian biotech firm Zymeworks have expanded their existing…

CanadaEli LillyLicensingOncologyPharmaceuticalResearchUSAZymeworks

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

02-10-2014

US pharma major Eli Lilly has said it will discontinue development of tabalumab, which is being studied…

Anti-Arthritics/RheumaticsEli LillyImmunologicalsPharmaceuticalResearchtabalumabUSA

FDA approves Lilly’s Trulicity to treat type 2 diabetes

FDA approves Lilly’s Trulicity to treat type 2 diabetes

19-09-2014

The US Food and Drug Administration yesterday approved pharma major Eli Lilly’s Trulicity (dulaglutide),…

BydureonDiabetesdulaglutideEli LillyPharmaceuticalRegulationTanzeumTrulicityUSAVictoza

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

31-08-2014

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their…

ActosDiabetesEli LillyFinancialLegalPharmaceuticalTakeda PharmaceuticalUSA

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

19-08-2014

The US Food and Drug Administration yesterday granted tentative approval for Basaglar (insulin glargine…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyInsulin Glargine [rDNA origin] InjectionLantusPharmaceuticalRegulationUSA

US FDA approves Jardiance for adults with type 2 diabetes

US FDA approves Jardiance for adults with type 2 diabetes

02-08-2014

The US Food and Drug Administration on Friday approved Jardiance (empagliflozin) tablets as an adjunct…

Boehringer IngelheimDiabetesEli LillyEuropeGermanyJardiancePharmaceuticalRegulationUSA

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

Lilly's Cyramza first FDA-approved drug for advanced gastric cancer after prior chemo

22-04-2014

The US Food and Drug Administration has approved pharma major Eli Lilly’s Cyramza (ramucirumab) as…

CyramzaEli LillyNorth AmericaOncologyPharmaceuticalRegulationUSA

1 to 25 of 31 results

Back to top